New, untreated myeloma study using four medicines
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 trial tests a combination of medicines (iberdomide, bortezomib, dexamethasone, and adding isatuximab) for people with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to improve disease control while checking safety in older adults who can take pills and attend frequent visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You sign a consent form and truly understand what the study involves
- You are age 65 or older when you sign up
- You have not received any anti-myeloma treatment before (except allowed short steroid or bone-strengthening medicines)
- Your myeloma has symptoms and test results that fit specific “organ damage” or lab/imaging criteria
- Your health status is good enough for study visits (ECOG score 0 to 2)
- Your blood and organ lab tests meet thresholds, including kidney function, liver enzymes, blood counts, and the ability to take medicines by mouth
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of four cancer-fighting drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) followed by a stem cell transplant for people newly diagnosed with multiple myeloma. The goal is to see if this approach can help patients live longer and control their disease better.
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
This trial tests different dosing schedules of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) together to treat multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find a dosing plan that works well and is tolerable for patients.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This trial tests a combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people with newly diagnosed high-risk multiple myeloma who cannot or choose not to have a stem cell transplant. It aims to see if this treatment helps control the disease better.
This Phase 2 study tests whether “isa-Rd” can safely and effectively treat people who have newly diagnosed multiple myeloma and are frail or much older. It may help those who are at higher risk of side effects from stronger, full-intensity chemotherapy.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.